The ROE as of September 2024 (TTM) for Y-mAbs Therapeutics, Inc. (YMAB) is -24.88%

According to Y-mAbs Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -24.88%. This represents a change of 296.57% compared to the average of -6.27% of the last 4 quarters.

Y-mAbs Therapeutics, Inc. (YMAB) Historical ROE (quarterly & annually)

How has YMAB ROE performed in the past?

The mean historical ROE of Y-mAbs Therapeutics, Inc. over the last ten years is -60.96%. The current -24.88% ROE has changed -59.18% with respect to the historical average. Over the past ten years (40 quarters), YMAB's ROE was at its highest in in the March 2021 quarter at 13.25%. The ROE was at its lowest in in the June 2022 quarter at -32.21%.

Y-mAbs Therapeutics, Inc. (YMAB) ROE by Quarter and Year

Discovering the peaks and valleys of Y-mAbs Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Y-mAbs Therapeutics, Inc. (YMAB) Average ROE

How has YMAB ROE performed in the past?

The current ROE of Y-mAbs Therapeutics, Inc. (YMAB) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Y-mAbs Therapeutics, Inc. (YMAB) ROE vs. Peers

How is YMAB’s ROE compared to its peers?

Y-mAbs Therapeutics, Inc.’s ROE is greater than TCR2 Therapeutics Inc. (-89.51%), greater than Revolution Medicines, Inc. (-34.57%), greater than Black Diamond Therapeutics, Inc. (-69.08%), greater than Atreca, Inc. (-195.22%), greater than Passage Bio, Inc. (-70.73%), greater than bluebird bio, Inc. (-72.35%), greater than Mersana Therapeutics, Inc. (-333.91%), greater than Zentalis Pharmaceuticals, Inc. (-44.23%), greater than Travere Therapeutics, Inc. (-102.43%), greater than Generation Bio Co. (-92.86%), greater than Kronos Bio, Inc. (-68.82%), greater than Erasca, Inc. (-131.94%), greater than C4 Therapeutics, Inc. (-44.60%), greater than Edgewise Therapeutics, Inc. (-28.01%), greater than Arcutis Biotherapeutics, Inc. (-145.41%), greater than Icosavax, Inc. (-41.24%), greater than Mirum Pharmaceuticals, Inc. (-43.47%), greater than VectivBio Holding AG (-56.92%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than Vaxcyte, Inc. (-30.07%), greater than Larimar Therapeutics, Inc. (-37.84%), greater than Syndax Pharmaceuticals, Inc. (-57.42%), greater than Merus N.V. (-36.33%), greater than Sutro Biopharma, Inc. (-97.19%),

Build a custom stock screener for Y-mAbs Therapeutics, Inc. (YMAB) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Y-mAbs Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Y-mAbs Therapeutics, Inc. (YMAB) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Y-mAbs Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.